Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Researchers sought to collect information on the characteristics of MS-related TN and on the frequency and type of medical/surgical treatments.
The researchers found that higher vitamin D predicted better cognitive performance, while smoking predicted worse performance.
The FDA has granted final approval to Bafiertam™ (monomethyl fumarate; Banner Life Sciences) for the treatment of relapsing forms of multiple sclerosis.
New data from the 5-year EXPAND open-label extension trial evaluating siponimod in patients with SPMS showed that the treatment slowed physical disability progression and provided cognitive benefits.
In patients with relapsing MS ponesimod was found to be superior to teriflunomide on annualized relapse rate, MRI activity and brain atrophy.
Switching from natalizumab to moderate DMT vs switching to high efficacy therapy in MS patients was associated with lower rates of no disease activity.
The FDA has accepted for review the supplemental Biologics License Application (sBLA) for a 2-hour Ocrevus (ocrelizumab; Genentech) infusion time, shortening the conventional infusion duration for patients with relapsing or primary progressive multiple sclerosis (MS).
The microbiota-gut-brain axis represents a bidirectional communication pathway through which the gut microbiota may influence the CNS.
Greater genetic predisposition for MS tied to imaging-observable changes in white matter in preteens